History of Changes for Study: NCT04855526

THC + CBD and Memory Study

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	Submitted Date	Changes
1	April 19, 2021	None (earliest Version on record)
2	October 27, 2021	Study Status, Arms and Interventions, Outcome Measures and Study Description
3	January 4, 2022	Recruitment Status and Study Status

Comparison Format:

Merged
Side-by-Side

Study Identification


Unique Protocol ID:	R-HHC-2019-0137
Brief Title:	THC + CBD and Memory Study
Official Title:	Effects of Marijuana on Memory-Related Neurochemistry and Neural Response
Secondary IDs:	126663 [Other Grant/Funding Number: Hartford Hospital]

Study Status


Record Verification:	April 2021
Overall Status:	Not yet recruiting
Study Start:	May 1, 2021
Primary Completion:	June 30, 2022 [Anticipated]
Study Completion:	June 30, 2022 [Anticipated]

First Submitted:	April 19, 2021
First Submitted that Met QC Criteria:	April 19, 2021
First Posted:	April 22, 2021 [Actual]

Last Update Submitted that Met QC Criteria:	April 19, 2021
Last Update Posted:	April 22, 2021 [Actual]

Sponsor/Collaborators


Sponsor:	Hartford Hospital
Responsible Party:	Principal Investigator Investigator: Godfrey Pearlson Official Title: Founding Director Olin Neuropsychiatry Research Center; Professor Yale University Affiliation: Hartford Hospital
Collaborators:	Yale University

Oversight


U.S. FDA-regulated Drug:	Yes
U.S. FDA-regulated Device:	No
Data Monitoring:	Yes

Study Description

Brief Summary:

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

Detailed Description:

With increased legalization and medicalization of marijuana (MJ), there is an urgent need to understand the acute effects of use. One of the most consistently observed cognitive outcomes associated with MJ use is memory dysfunction, which may have a substantial impact on daily life in individuals using MJ for recreational or medicinal purposes. Notably, there are numerous preparations of MJ with varying proportions of cannabinoids, which may differ in behavioral and cognitive effects. For instance, there is emerging evidence that acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic resonance imaging (fMRI) activation, but cannabidiol (CBD) may mitigate some of these impairments. Given the role of glutamate in learning and memory, we suggest that these effects may be subserved, in part, by glutamatergic mechanisms. We will use magnetic resonance spectroscopy (MRS) to non-invasively measure glutamate in order to explore the neurochemical underpinnings of memory-related fMRI response changes following acute administration of THC and CBD in a randomized, double-blind, placebo-controlled, cross-over design. A total of 9 healthy participants ages 18-40 will be enrolled. Participants will first undergo one screening visit (~4 hours), comprising informed consent, assessment of health history, psychiatric diagnoses, cognitive function, and substance use history, and a structural MRI session. This will be followed by 3 separate MJ dose visits (~4 hours each), at which participants will complete neuroimaging after administration of one of 3 preparations of vaporized MJ in a randomized, counterbalanced, double-blinded fashion: 1) high THC and no CBD (THC), 2) high THC and high CBD (THC+CBD), and 3) no THC and no CBD (placebo MJ). As in our ongoing studies, bulk MJ plant material will be provided by the National Institute on Drug Abuse. MJ dose visits will comprise MJ administration, blood collection, MRS/fMRI scan, subjective reports, and a brief cognitive assessment.

Conditions


Conditions:	Marijuana Use Cannabis Use Cannabis Intoxication
Keywords:	marijuana cannabidiol memory THC cannabis intoxication MRI glutamate MRS

Study Design


Study Type:	Interventional
Primary Purpose:	Other
Study Phase:	Early Phase 1
Interventional Study Model:	Crossover Assignment
Number of Arms:	3
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:	Randomized
Enrollment:	9 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Occasional Users - High THC and High CBD Dose People who smoke marijuana occasionally will be given a dose of high THC high CBD marijuana at the study visit	Drug: High THC/High CBD Marihuana high THC (65 mg THC) and high CBD (50 mg CBD)
Experimental: Occassional Users - High THC and No CBD Dose People who smoke marijuana occasionally will be given a dose of high THC and no CBD marijuana at the study visit	Drug: High THC/No CBD Marihuana high THC (65 mg THC) and no CBD (0 mg CBD)
Experimental: Occassional Users - No THC and No CBD Dose People who smoke marijuana occasionally will be given a dose of marijuana that contains no THC or CBD	Drug: No THC/No CBD Marihuana no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug

Outcome Measures


Primary Outcome Measures:
1.	fMRI response [ Time Frame: approximately 1 hour following drug administration ] Blood oxygen level dependent functional magnetic resonance imaging (fMRI) response during the relational and item specific encoding task. fMRI response will be evaluated during the encoding phase (relational vs. item encoding), item recognition phase (hits vs. misses for item-specific encoding, and hits vs. misses for relational encoding), and associative recognition phase (hits vs. misses).
2.	Glutamate [ Time Frame: approximately 1 hour following drug administration ] Magnetic resonance spectroscopy (MRS)-acquired glutamate containing compounds (Glx).
Secondary Outcome Measures:
1.	HVLT-R performance [ Time Frame: Approximately 2.50 hours after drug administration ] The Hopkins Verbal Learning Test-Revised will ascertain verbal list learning and immediate and delayed recall (~15min); alternate forms have been validated, and the order of versions participants receive will be randomized
2.	Performance on CHARLIE cognitive task [ Time Frame: Approximately 3.00 hours after drug administration ] This is a computer-based cognitive battery that administers the Digit Span and Letter/Number Sequencing Test (working memory) and the Digit Symbol Coding test (processing speed). It should take about 10 minutes to complete.
3.	Blood THC and CBD concentration testing [ Time Frame: Immediately after drug administration (~0.25 hours after drug administration) ] A blood sample will be taken once per dose visit to assess the concentration of the following metabolites: delta-9-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-Nor-9-Carboxy-tetrahydrocannabinol (THCCOOH), tetrahydrocannabinol-Glucuronide, THCCOOH-Glucuronide, cannabinol (CBN), and cannabidiol (CBD).
4.	Subjective effects on drug effects questionnaire [ Time Frame: Post drug administration at: 0.00 hours (immediately after); 1.0 hours; 2.0 hours; 3.0 hours ] This self-report will be used to assess subjective reports every 60 minutes throughout the dose visit days. These subjective ratings will be obtained using rapidly completed Visual Analog Scales (VASs) scored on a 0-100 scale. Items include: Do you feel a drug effect right now?, Are you high right now?, Do you dislike any of the effects you are feeling right now?, Do you like any of the effects you are feeling right now? and Would you like more of the drug you took, right now?

Eligibility


Minimum Age:	18 Years
Maximum Age:	40 Years
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	Yes
Criteria:	Inclusion Criteria: Right-handed Prior MJ users (has used MJ at least once in the past year, but no more than 1x/month in the past 12 months) Medically healthy (as determined by medical history and treatment) Adequate comprehension of English in order to complete study materials Acceptable birth control method for women (i.e., no copper IUD or any device that is not MRI safe) Exclusion Criteria: Participant currently uses psychoactive medications or substances Psychiatric diagnoses (determined by DSM-V) Participant heavily or regularly uses MJ (more than 1x/month in the past year) Current or past substance dependence (including MJ) Positive urine toxicology screens Positive pregnancy screens MRI contraindications (e.g., heart pacemaker)

Contacts/Locations


Central Contact Person:	Chelsea N Meagher, BA Telephone: 860-545-7106 Email: chelsea.meagher@hhchealth.org
Central Contact Backup:	Diana G King, BA Telephone: 860-545-7563 Email: diana.king@hhchealth.org
Study Officials:	Godfrey Pearlson, MD Principal Investigator Hartford Hospital - Olin Neuropsychiatry Research Center; Yale University
	Alecia Dager, PhD Principal Investigator Hartford Hospital - Olin Neuropsychiatry Research Center; Yale University
	Michael Stevens, PhD Principal Investigator Hartford Hospital - Olin Neuropsychiatry Research Center
Locations:

IPDSharing


Plan to Share IPD:

References


Citations:
Links:
Available IPD/Information: